ArticleAntioxidants (Basel, Switzerland)2022
Article in Antioxidants (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 13 citations in OpenAlex.
- Exploring the HNE-inhibitory potential of in silico selected Moringa oleifera defense proteins.Journal of computer-aided molecular design · 2026Article
- Comparative inhibitory effects of phillyrin and phillygenin on elastase: mechanisms and therapeutic potential.Frontiers in nutrition · 2026Article
- [Protective effect ofNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025Article
- Investigating cigarette smoke-induced airway inflammation and sperm activity impairment in rats based on cilia-associated proteins.3 Biotech · 2025Article
- The influence of spatial distribution and transcriptional regulation of secondary metabolites on the bioactivities ofHeliyon · 2024Article
- UnripeNutrients · 2023Article
- Bulb ofJournal of microbiology and biotechnology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
Cigarette smoke (CS) is the major factor in the development of chronic obstructive pulmonary disease (COPD), the third leading cause of death worldwide. Furthermore, although
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.